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T cell checkpoint blockade and T cell costimulation,
two types of immunotherapy undergoing active clinical
investigation, have led to improved outcomes for
patients with different types of advanced cancer. Given
that these approaches can result in durable remissions,
there is interest in increasing the number of patients
who can benefit from them. Interestingly, there is evi-
dence that patients who ultimately respond to T cell tar-
geted immunotherapy are immunologically primed prior
to treatment with an immune-activated tumor microen-
vironment. Importantly, recent data suggest that mono-
clonal antibodies (mAbs) against tumor antigens
generate tumor-specific T cell activity. Our group has
demonstrated that TA99, a murine IgG2a mAb against
the melanosomal TYRP1 enzyme, can induce tumor-
specific T cell responses; and others have shown that
breast cancer patients treated with the humanized anti-
HER2 IgG1 mAb trastuzumab also develop tumor-speci-
fic T cell responses. This raises the possibility that such
antibodies may potentiate responses to immune check-
point blockade and costimulation. While others have
tested T cell stimulatory therapy in the setting of tumor
targeted mAb treatment, we are not aware of a compari-
son of multiple T cell stimulatory mAbs in this context.
We have therefore directly compared the ability of
checkpoint blocking mAbs (against PD-1, PD-L1, and
CTLA-4) and costimulatory mAbs (against OX40,
4-1BB, and GITR) to be potentiated by TA99. Using a
syngeneic and poorly immunogenic murine melanoma
model we have found enhanced tumor control with
TA99 in combination with anti-CTLA-4 and anti-OX40
respectively. Crucially, TA99 in combination with these
agents results in prolonged tumor-specific immunologic
memory. This suggests that these regimens, and analo-
gous immunotherapeutic couplets with other tumor-
targeted mAbs, may yield durable anti-tumor activity in
patients and should be explored in the clinic.
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